Labcorp said its Board of Directors declared a cash dividend of $0.72 per share of common stock on July 25, 2024.

8-KRegulation FD DisclosureFiled Jul 25, 2024Period of report Jul 24, 2024Summary published (UTC) Oct 25, 2026

Key points

AI summary

Labcorp said its Board of Directors declared a cash dividend of $0.72 per share of common stock on July 25, 2024.
The company said the dividend is payable on September 13, 2024 to stockholders of record as of the close of business on August 29, 2024.
The company reported the dividend announcement under Item 7.01, Regulation FD Disclosure, on Form 8-K, and attached the press release dated July 25, 2024 as Exhibit 99.1.
In its press release, the company said it has more than 67,000 employees serving clients in approximately 100 countries, and that it supported 84% of the new drugs and therapeutic products approved by the FDA in 2023.

Summary

AI-written

Analysis scope · Filing body and confirmed press-release exhibitWe analyzed the filing body and confirmed exhibits. This is not a review of other exhibits, investor presentations or the full earnings call.

Cash dividend of $0.72 per share declared

Labcorp said its Board of Directors declared a cash dividend of $0.72 per share of common stock on July 25, 2024.

Source · Based on the filing body and exhibits

Dividend payment date and record date

The company said the dividend is payable on September 13, 2024 to stockholders of record as of the close of business on August 29, 2024.

Source · Based on the filing body and exhibits

Filing format: Form 8-K Item 7.01 and press release

The company reported the dividend announcement under Item 7.01, Regulation FD Disclosure, on Form 8-K, and attached the press release dated July 25, 2024 as Exhibit 99.1.

Source · Based on the filing body and exhibits

Company profile figures in press release

In its press release, the company said it has more than 67,000 employees serving clients in approximately 100 countries, and that it supported 84% of the new drugs and therapeutic products approved by the FDA in 2023.

Source · Based on the filing body and exhibits

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.

View the original filing on SEC EDGAR ↗

Unauthorized scraping, data storage and database creation prohibited

Without prior written consent, you must not crawl or scrape data compiled and organized by Chickstock or its analysis and summaries, or collect them repeatedly or in bulk for storage, ingestion or database creation. Repurposing, redistribution, sale and use to build other services are also prohibited.

Unauthorized use may result in access restrictions, demands to stop infringement and delete copies, and claims for damages. Violations of applicable law may also give rise to criminal liability.

Uses permitted by law, the Terms of Service or a separate agreement remain subject to their respective scope. Rights in individual source materials, including original filings, remain with their respective rights holders.